Home › Companies › CLDX

Celldex Therapeutics

Most recent annual filing: 2026-02-15

Catalyst timeline

2 trackedQuarter catalyst calendar →
  1. Barzolvolimab commercial manufacturing update2026Barzolvolimab commercial manufacturing update, 2026, routine
  2. Barzolvolimab Atopic Dermatitis Ph2 toplinelate 2026Barzolvolimab Atopic Dermatitis Ph2 topline, late 2026, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

Technology platforms

Bispecific Antibody Platform

Next generation bispecific antibody platform supporting pipeline expansion with additional candidates for inflammatory diseases. Targets selected based on new science and compatibility with existing antibody programs in bispecific formats. Focus on emerging pathways controlling inflammatory diseases.

Discontinued (2)

Biotech Distilled coverage (5)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.